A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
NCT06810934 is a phase 1/2 interventional trial sponsored by Kara Chew. As of 21 Nov 2026, it is recruiting participants. It studies CoTend-BXBB, CoTend-s3BXBB and Placebo in COVID-19 and SARS-CoV-2 Infection. The registry lists an enrollment of 80 participants at 2 sites in 1 country. The registry lists a start date of 21 Oct 2025 and a primary completion date of 31 Dec 2027. 2 of its registered investigators have a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06810934 |
| Status | Recruiting |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | Kara Chew |
| Enrollment | 80 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | COVID-19 and SARS-CoV-2 Infection |
| Drugs | CoTend-BXBB, CoTend-s3BXBB and Placebo |
| Start | 21 Oct 2025 |
| Primary completion | 31 Dec 2027 |
| Study completion | 31 Oct 2029 |
| Last update posted | 18 Aug 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Dennis Hartigan-O'Connor, MD, PhD
University of California, Davis
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Recruiting
- Recruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06810934
Each answer restates registry values shown on this page.
What is NCT06810934?
NCT06810934 is a phase 1/2 interventional trial sponsored by Kara Chew. It studies CoTend-BXBB, CoTend-s3BXBB and Placebo in COVID-19 and SARS-CoV-2 Infection.
Is NCT06810934 recruiting?
As of 21 Nov 2026, it is recruiting participants. 2 of its 2 sites list their own status as recruiting.
Who leads NCT06810934?
The registry names Dennis Hartigan-O'Connor, MD, PhD (principal investigator, University of California, Davis), Kara Chew, MD, MS (principal investigator, University of California, Los Angeles) and Steven Deeks, MD (principal investigator, University of California, San Francisco) as overall officials.
Where does NCT06810934 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06810934 study?
The registered drug and biological interventions are CoTend-BXBB, CoTend-s3BXBB and Placebo.
When is NCT06810934 expected to complete?
The registry lists a primary completion date of 31 Dec 2027 and a study completion date of 31 Oct 2029. The sponsor last updated the record on 18 Aug 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.